Advances in genomic testing techniques have greatly improved our understanding of germline mutations associated with predisposition to hematologic malignancies is rapidly increasing. This information is essential for accurate patient diagnosis and treatment planning, hematopoietic stem cell donor selection, and genetic counseling for patient families. Germline predispositions have recently been revealed to exist in myeloid and lymphoid malignancies. This article reviews the causative genes and clinical characteristics related to germline predispositions to lymphoid malignancies.